Kidney, Urology, and Digestive Systems Review Branch – KUDS
Dr. Jonathan Ivins
Chief
Review Branch Summary
KUDS will review applications on basic and clinical aspects of gastrointestinal, hepatobiliary, pancreatic, kidney, urinary tract and male genital system physiology and pathobiology, as well as the disposition and action of nutrients and xenobiotics. In addition, the KUDS Review Branch will review applications aimed at development and evaluation of new techniques, therapies and treatments related to the disorders of the GI tract, hepatobiliary, pancreas, kidney, urinary tract, and male genital system. Investigators may employ a broad range of basic and clinical research methods including pharmacologic, chemical and biochemical approaches, genetics, genomics and proteomics, molecular and cell biology techniques and animal models. Patient-oriented studies including pediatric gastroenterology, renal, urinary and male genital system are included in this IRG, but large population studies and randomized clinical trials involving digestive disorders, kidney, urinary and male genital systems will be reviewed elsewhere.
Study Sections
- Digestive System Host Defense, Microbial Interactions and Immune and Inflammatory Diseases DHMI
- Digestive and Nutrient Physiology and Diseases DNPD
- Digestive Sciences Small Business Activities [SBIR/STTR] Special Emphasis Panel KUDS (10)
- Renal and Urological Sciences Small Business Activities [SBIR/STTR] Special Emphasis Panel KUDS (11)
- Hepatobiliary Pathophysiology Study Section HBPP
- Kidney and Urological Systems Function and Dysfunction KUFD
- Pathobiology of Kidney Disease Study Section PBKD
- Systemic Injury by Environmental Exposure *Ends after October/Nov 2022 review meetings SIEE
- Xenobiotic and Nutrient Disposition and Action *Ends after October/Nov 2022 review meetings XNDA
- New! Drug and Biologic Disposition and Toxicity*Begins for upcoming October/November 2022 application deadlines, with first review dates in February/March 2023 DBDT
- New! Environmental Determinants of Disease*Begins for upcoming October/November 2022 application deadlines, with first review dates in February/March 2023 EDD
